RNAi therapeutics rarely interact with drug metabolizing enzymes or drug transporters and therefore have low liability for drug-drug interactions. This presentation with present a case study of Givosiran, a RNAi therapeutic for treatment of Acute Hepatic Porphyria, where a pharmacological drug-drug interaction due to the effect of givosiran on the heme pathway was evaluated.
Understand the DDI perspectives for novel therapeutics such as RNAi
Explore new mechanisms for DDIs
Understand the implications of DDIs on clinical pharmacology strategies for RNAi therapeutics